What is the official ID of this bill?
The official print number for this legislation is S 2559.
Opioid Fee on Manufacturers Funds Addiction Treatment and Patient Care.
This law establishes a new fee of 1 cent per milligram on manufacturers and importers of active opioid pain relievers. The revenue generated will be exclusively dedicated to funding state substance abuse treatment programs, including building new facilities and expanding services. Crucially, mechanisms are mandated to ensure that eligible patients, such as those with cancer or in hospice care, receive rebates or discounts so they do not bear the economic burden of this new fee.
Key points
A new fee of 1 cent per milligram is imposed on manufacturers and importers of active opioid pain relievers.
All revenue collected (minus patient rebates) is earmarked for expanding state substance abuse and opioid addiction treatment efforts.
Cancer patients, hospice patients, and others with specific medical needs are protected from paying the fee through mandatory rebate or discount programs.
Funds will support establishing new treatment centers, sober living facilities, and care for infants born with neonatal abstinence syndrome.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.